Nirsevimab Linked to Lower Infant Hospitalization Risk Than Maternal Vaccine

First real-world comparison shows lower hospitalization and severe illness rates with infant immunization vs maternal vaccination.

1

Nirsevimab administration in infants is linked to a lower risk of hospitalization for respiratory syncytial virus compared to maternal vaccination.
2

The study evaluated over 42,000 newborns during the 2024-2025 RSV season using the French National Health Data System.
3

Infants receiving nirsevimab had a 26% lower likelihood of RSV-associated lower respiratory tract infection compared to those with maternal vaccination.
4

Severe outcomes, including PICU admission and ventilatory support, were less common in the nirsevimab group.
5

The findings suggest that nirsevimab may provide better protection against RSV-related hospitalization in early infancy.

1